Indian industry warns of 'incapacitating' effect of large foreign takeovers
This article was originally published in Scrip
Second rung Indian firms, which account for less than 20% of the country's pharmaceutical exports, cannot fill the shoes of first tier companies if the latter continue to be acquired by foreign firms, a leading domestic industry body has told a government committee looking into issues concerning India's foreign direct investment (FDI) policy in the sector.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.